US Could Save Nearly $1 Billion With Pembrolizumab Dosing Change
This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.
In this video, Daniel A. Goldstein, MD, of the Davidoff Cancer Center in Israel, discusses a study that found that a change to weight-based pembrolizumab dosing in first-line PD-L1–positive non–small-cell lung cancer could save nearly $1 billion in US healthcare expenditures.
Goldstein presented results of the study (abstract 9013) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
